-
ADA Symposium to review year’s important advances in diabetes research
Martin G. Myers, Jr., MD, PhD, will provide a year in review of basic science discoveries. Jennifer Green, MD, will look back at clinical research. Eric Ravussin, PhD, will summarize breakthroughs in translational diabetes research.
-
Session to explore GLP-1, GIP RAs in mental disorders, addiction, and more
Roger S. McIntyre, MD, FRCPC, and other investigators will outline unanticipated effects of using incretin receptor agonists outside of the clinical impact on weight loss and metabolic disorders.
-
Experts will provide update on latest advances in pediatric type 2 diabetes
The use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are just two of the new considerations, as panelist Megan Oberle Bensignor, MD, MSHP, will discuss.
-
Panel to spotlight potential of continuous ketone monitoring
Just as continuous glucose monitoring is transforming diabetes care with improved glucose management, continuous ketone monitoring could dramatically improve patient outcomes. Experts, including Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD, will explain how.
-
Under the Knife—Perioperative Considerations for Patients with Diabetic Foot Infections
Brandon M. Brooks, DPM, MPH, previews a presentation at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Saturday, June 21, at 3:15 p.m. CT.
-
Implementing Improvements in Care Delivery
Jack Westfall, MD, MPH, previews a presentation at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Saturday, June 21, at 1:30 p.m. CT.
-
MariTide investigators will review trial data for monthly obesity treatment
Among the panelists, Ania M. Jastreboff, MD, PhD, will discuss results for participants without type 2 diabetes, and Harold Bays, MD, will discuss results for participants with the disease.
-
Researchers to share PATHWEIGH ‘roadmap’ for implementing weight management processes into primary care
PATHWEIGH focuses on reducing excess body weight and weight-related medical complications by providing patients with highly individualized care based on their needs, access, and preferences.
-
Symposium will discuss QWINT results that could signal paradigm shift in basal insulin dosing
Chantal Mathieu, MD, PhD, and other researchers will explain the latest data from a series of pivotal trials on once-weekly insulin efsitora alfa.
-
Investigators will present findings from treatment phase of CATALYST trial
Researchers, including Vivian Fonseca, MD, will return to the Scientific Sessions with new data on mifepristone use to treat people with hypercortisolism and difficult-to-manage type 2 diabetes.